Differential Effects of Fibroblast Growth Factors on Expression of Genes of the Plasminogen Activator and Insulin-like Growth Factor Systems by Human Breast Fibroblasts

Summary In breast stroma urokinase plasminogen activator (uPA) is predominantly expressed by fibroblasts located in the near vicinity of tumor cells, and fibroblast-derived insulin-like growth factor-1 (IGF-1) may be involved in inhibiting the expression of uPA in these fibroblasts. To investigate a possible role for fibroblast growth factors (FGFs), we evaluated the expression of components of the PA system and the IGF system in normal and tumor-tissue-derived human breast fibroblasts exposed to various FGFs in vitro. mRNA analysis revealed that FGF-1, FGF-2 and FGF-4 induced the mRNA expression levels of uPA, tPA, uPAR, PAI-1 and PAI-2, and reduced those of IGF-1, IGF-1R, IGF-2R and IGFBP-4, without significantly affecting the levels of IGFBP-3, IGFBP-5 and IGFBP-6 mRNA. Concerning the expression of IGF-2 mRNA, the effects mediated by FGF-1, FGF-2 and FGF-4 were divergent. In general, the effects elicited by FGF-1 on the various mRNA levels studied were rapid and short-term. Those mediated by FGF-2 overall lagged behind but were longer-lasting. For FGF-4 an in between pattern was observed. Blocking transcription and translation demonstrated that a) both the FGF-1 and FGF-2 induced effects were the result of altered gene transcription or mRNA stability, b) the short-term effects mediated by FGF-1 and FGF-2 required de novo protein synthesis, and c) the long-term effects elicited by FGF-2 did not depend on de novo protein synthesis during the first 24 h, but were triggered by proteins produced or made available thereafter. The data presented propose that of the FGFs studied (FGF-1, -2, -4, -5, and -7), FGF-2 is the most attractive target for therapeutical strategies aimed at diminishing the contribution of stromal fibroblasts in the PA-directed breast tumor proteolysis.

[1]  J. Foekens,et al.  Cytokine‐regulated urokinase‐type‐plasminogen‐activator (uPA) production by human breast fibroblasts in vitro , 1999, Breast Cancer Research and Treatment.

[2]  K. Cullen,et al.  Paracrine/autocrine regulation of breast cancer by the insulin-like growth factors , 1998, Breast Cancer Research and Treatment.

[3]  Adrian V. Lee,et al.  Igf system components as prognostic markers in breast cancer , 1998, Breast Cancer Research and Treatment.

[4]  G. Neufeld,et al.  Similarities and differences between the vascular endothelial growth factor (VEGF) splice variants , 1996, Cancer and Metastasis Reviews.

[5]  M. Ellis,et al.  Insulin-like growth factors in human breast cancer , 2004, Breast Cancer Research and Treatment.

[6]  C. Sweep,et al.  Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. , 2001, Journal of the National Cancer Institute.

[7]  J. Oh,et al.  Up-regulation of urokinase-type plasminogen activator by insulin-like growth factor-I depends upon phosphatidylinositol-3 kinase and mitogen-activated protein kinase kinase. , 2001, Cancer research.

[8]  I. McCutcheon,et al.  The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. , 2000, Endocrine reviews.

[9]  R. Baxter Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities. , 2000, American journal of physiology. Endocrinology and metabolism.

[10]  M. Nugent,et al.  Mechanisms of fibroblast growth factor 2 intracellular processing: a kinetic analysis of the role of heparan sulfate proteoglycans. , 2000, Biochemistry.

[11]  H L Chen,et al.  Differential regulation of FGF-1 and -2 mitogenic activity is related to their kinetics of binding to heparan sulfate in MDA-MB-231 human breast cancer cells. , 2000, Biochemical and biophysical research communications.

[12]  P. Andreasen,et al.  The plasminogen activation system in tumor growth, invasion, and metastasis , 2000, Cellular and Molecular Life Sciences CMLS.

[13]  D. Ribatti,et al.  In vivo angiogenic activity of urokinase: role of endogenous fibroblast growth factor-2. , 1999, Journal of cell science.

[14]  J. Foekens,et al.  Insulin-like growth factor 1 (IGF-1) and urokinase-type plasminogen activator (uPA) are inversely related in human breast fibroblasts , 1999, Molecular and Cellular Endocrinology.

[15]  R. Baxter,et al.  The IGF axis and programmed cell death , 1999, Immunology and cell biology.

[16]  V. Speirs,et al.  Production of VEGF and expression of the VEGF receptors Flt-1 and KDR in primary cultures of epithelial and stromal cells derived from breast tumours , 1999, British Journal of Cancer.

[17]  S. Shibata,et al.  Ets-1 transcription factor-mediated urokinase-type plasminogen activator expression and invasion in glioma cells stimulated by serum and basic fibroblast growth factors. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[18]  J. Foekens,et al.  Clinical relevance of the urokinase plasminogen activator system in breast cancer , 1999, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[19]  R. O'Connor,et al.  Survival factors and apoptosis. , 1998, Advances in biochemical engineering/biotechnology.

[20]  D. Hume,et al.  Cooperation of two PEA3/AP1 sites in uPA gene induction by TPA and FGF-2. , 1997, Gene.

[21]  C. López-Otín,et al.  Regulation of collagenase-3 expression in human breast carcinomas is mediated by stromal-epithelial cell interactions. , 1997, Cancer research.

[22]  J. Aparicio,et al.  Low levels of basic fibroblast growth factor (bFGF) are associated with a poor prognosis in human breast carcinoma. , 1997, British Journal of Cancer.

[23]  S. Mandriota,et al.  Vascular endothelial growth factor-induced in vitro angiogenesis and plasminogen activator expression are dependent on endogenous basic fibroblast growth factor. , 1997, Journal of cell science.

[24]  P. Eriksson,et al.  Differential regulation of the plasminogen activator inhibitor-1 (PAI-1) gene expression by growth factors and progesterone in human endometrial stromal cells. , 1997, Molecular human reproduction.

[25]  H. Höfler,et al.  Clinical Impact of the Plasminogen Activation System in Tumor Invasion and Metastasis: Prognostic Relevance and Target for Therapy , 1997, Thrombosis and Haemostasis.

[26]  M. Jalkanen,et al.  Is the sensitivity of cells for FGF-1 and FGF-2 regulated by cell surface heparan sulfate proteoglycans? , 1997, European journal of cell biology.

[27]  S. Shousha,et al.  The location of acidic fibroblast growth factor in the breast is dependent on the activity of proteases present in breast cancer tissue. , 1997, British Journal of Cancer.

[28]  A. Geurts-Moespot,et al.  A Sensitive and Robust Assay for Urokinase and Tissue-Type Plasminogen Activators (Upa and Tpa) and Their Inhibitor Type I (Pai-1) in Breast Tumor Cytosols , 1997, The International journal of biological markers.

[29]  S. Shousha,et al.  Fibroblast growth factor 2 in breast cancer: occurrence and prognostic significance. , 1997, British Journal of Cancer.

[30]  R. Bast,et al.  Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. , 1996, Journal of the National Cancer Institute.

[31]  M. Duffy,et al.  Urokinase plasminogen activator as a predictor of aggressive disease in breast cancer. , 1996, Enzyme & protein.

[32]  B. Nielsen,et al.  Messenger RNA for urokinase plasminogen activator is expressed in myofibroblasts adjacent to cancer cells in human breast cancer. , 1996, Laboratory investigation; a journal of technical methods and pathology.

[33]  J. Foekens,et al.  Transforming growth factor beta secretion from primary breast cancer fibroblasts , 1995, Molecular and Cellular Endocrinology.

[34]  F. Bertucci,et al.  Expression of fgf and fgf receptor genes in human breast cancer , 1995, International journal of cancer.

[35]  P. Chambon,et al.  Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[36]  F. Sarkar,et al.  Biologic and clinical significance of basic fibroblast growth factor immunostaining in breast carcinoma. , 1995, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[37]  R. Rosato,et al.  Interactions between insulin-like growth factor-I (IGF-I) and the system of plasminogen activators and their inhibitors in the control of IGF-binding protein-3 production and proteolysis in human osteosarcoma cells. , 1994, Endocrinology.

[38]  B. Vandenbunder,et al.  Stromal expression of c-Ets1 transcription factor correlates with tumor invasion. , 1994, Cancer research.

[39]  N. Brünner,et al.  Expression of uPA and its receptor by both neoplastic and stromal cells during xenograft invasion , 1994, International journal of cancer.

[40]  S. Leinster,et al.  Comparative expression of fibroblast growth factor mRNAs in benign and malignant breast disease. , 1994, British Journal of Cancer.

[41]  B. Olwin,et al.  Activating and inhibitory heparin sequences for FGF-2 (basic FGF). Distinct requirements for FGF-1, FGF-2, and FGF-4. , 1993, The Journal of biological chemistry.

[42]  L. Orci,et al.  Upregulation of urokinase receptor expression on migrating endothelial cells , 1993, The Journal of cell biology.

[43]  B. Nielsen,et al.  An alternatively spliced variant of mRNA for the human receptor for urokinase plasminogen activator , 1993, FEBS letters.

[44]  M. Loriot,et al.  Stromelysin 3 belongs to a subgroup of proteinases expressed in breast carcinoma fibroblastic cells and possibly implicated in tumor progression. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[45]  D. Johnson,et al.  Structural and functional diversity in the FGF receptor multigene family. , 1993, Advances in cancer research.

[46]  P. Campbell,et al.  Involvement of the plasmin system in dissociation of the insulin-like growth factor-binding protein complex. , 1992, Endocrinology.

[47]  J. Foekens,et al.  Stromal influences on breast cancer cell growth. , 1992, British Journal of Cancer.

[48]  G. Mavrothalassitis,et al.  The human ETS1 gene: genomic structure, promoter characterization and alternative splicing. , 1991, Oncogene.

[49]  P. Chambon,et al.  A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas , 1990, Nature.

[50]  D. Rifkin,et al.  Release of basic fibroblast growth factor-heparan sulfate complexes from endothelial cells by plasminogen activator-mediated proteolytic activity , 1990, The Journal of cell biology.

[51]  J. Lélias,et al.  High molecular mass forms of basic fibroblast growth factor are initiated by alternative CUG codons. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[52]  F. V. Schaik,et al.  Sequence of cDNA encoding human insulin-like growth factor I precursor , 1983, Nature.